What is Definium Therapeutics, Inc.?
, a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.88B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 681,951 shares $3.0M | 0 |
| 3-6months | 558,131 shares $2.6M | 0 |
| 6-9months | 343,151 shares $797k | 0 |
| 9-12months | 342,667 shares $561k | 0 |